Internal R&D vs. CROs: AstraZeneca, Novartis Tout Advantages Of Staying In-House
This article was originally published in The Pink Sheet Daily
Novartis reports savings of $100 mil. by decreasing its use of contract research organizations. AstraZeneca sees improved R&D productivity by relying less on CROs and by conducting clinical trials outside the U.S.
You may also be interested in...
Each outsourced clinical trial patient could save GSK up to $15,000, CEO Garnier estimates. The company is exploring a number of ways to control R&D costs, the exec says, citing electronic data capture as another potential option.
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.